Novo Ventures co-leads US$83m series C financing in Lava Therapeutics
Summary
The financing will accelerate the advancement of LAVAs immuno-oncology pipeline and its powerful bispecific gamma-delta T cell engager programs into multiple proof-of-concept clinical trials expected to start in 2021 for the treatment of solid tumours and hematologic malignancies. We are impressed by the preclinical data generated by LAVA to date, which validates the companys platform and are delighted to support such a highly experienced team as they transition into a clinical-stage organization. This investment reflects Novo Ventures strategy of supporting world class companies by backing seasoned entrepreneurs and promising science in areas of major unmet medical need. Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, said: "We believe our targeted approach, leveraging the unique features of gamma9-delta2 T cells with innovative bispecific antibodies, will deliver novel T cell-based therapies offering considerable advantages over todays oncology treatments. Further information: http://www.novoholdings.dk LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.